Lipocine

Lipocine Inc., founded in Salt Lake City, is a specialty pharmaceutical company dedicated to advancing oral drug delivery technology for men's and women's health. The company focuses on developing treatments for metabolic and endocrine disorders, aiming to improve drug absorption and patient compliance. Lipocine's flagship product, TLANDO®, is an FDA-approved oral testosterone replacement therapy that does not require dose titration, highlighting their commitment to innovative healthcare solutions.

Notable figures associated with Lipocine include experts in pharmaceutical development and endocrinology. The company has secured significant investments from leading healthcare investors, bolstering its research and development efforts. Key achievements include the FDA approval of TLANDO® and the advancement of a robust pipeline targeting various neuroendocrine and metabolic disorders. Lipocine's impact is marked by its potential to enhance patient outcomes through improved drug delivery methods and accessible treatment options.